MedTrace Logo

Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil

NCT05034393 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 308

Last updated 2023-10-06

No results posted yet for this study

Summary

This study aims to describe in detail the patient journey from diagnosis to the beginning of treatment and patterns of care of hormone receptor- positive, HER2-negative de novo or recurrent metastatic breast cancer between January 2018 and December 2020 in Brazil.

Conditions

Sponsors & Collaborators

  • Brazilian Breast Cancer Study Group (GBECAM)

    collaborator UNKNOWN

  • Latin American Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Gustavo Werutsky · Latin American Cooperative Oncology Group

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-04
Primary Completion
2023-02-27
Completion
2023-02-27

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05034393 on ClinicalTrials.gov